Physician profile
Varsha Tulpule
NPI 1801214903
$7,014.26
in general payments reported to CMS, 2019-2025
28 companies · $697 in 2025
The $697 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $295 · 2021: $4,126 · 2022: $530 · 2023: $446 · 2024: $317 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,435 · Education: $25.60.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,435.10 |
| Education | $25.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exelixis INC. | $4,460.13 | 2021-2025 | Cabometyx |
| Emd Serono, INC. | $359.01 | 2023-2025 | Bavencio |
| Astrazeneca Pharmaceuticals LP | $297.96 | 2020-2025 | Calquence |
| Amgen INC. | $289.77 | 2019-2020 | |
| Incyte Corporation | $161.70 | 2019-2023 | Monjuvi |
| Alexion Pharmaceuticals, INC. | $151.78 | 2019-2024 | Ultomiris |
| Celgene Corporation | $150.29 | 2019-2023 | |
| Genentech USA, INC. | $148.29 | 2019 | |
| Adc Therapeutics America, INC. | $125.16 | 2021 | |
| Sobi, INC | $114.42 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $111.75 | 2022-2025 | |
| Genzyme Corporation | $96.12 | 2025 | |
| Astellas Pharma US INC | $86.99 | 2022-2023 | Padcev |
| Janssen Biotech, INC. | $79.45 | 2025 | Erleada |
| Novartis Pharmaceuticals Corporation | $48.18 | 2023 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $48.14 | 2019 | |
| Abbvie INC. | $44.21 | 2022-2023 | Venclexta |
| Pfizer INC. | $40.80 | 2022-2024 | |
| Alnylam Pharmaceuticals INC. | $29.42 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.55 | 2024 | Ninlaro |
| Eisai INC. | $24.50 | 2024 | |
| Beone Medicines USA, INC. | $23.49 | 2025 | Brukinsa |
| Merck Sharp & Dohme LLC | $22.74 | 2025 | Keytruda, Welireg |
| Ipsen Biopharmaceuticals, INC | $20.51 | 2019 | |
| Glaxosmithkline, LLC. | $18.59 | 2021 | |
| Seagen INC. | $17.24 | 2020 | |
| Puma Biotechnology, INC. | $15.07 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Varsha Tulpule listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.